Melanotan II
- Category
- Skin & Cosmetic
- Administration routes
- Injectable
- Regulatory status
- Not FDA-approved
What it is
A cyclic analog of alpha-MSH that activates the melanocortin receptors, sold for tanning, erectile function, and appetite suppression. Human evidence is good for erections and tanning but weak for appetite and sun protection. Most users get nausea and flushing, and the real concern is that it stimulates melanocytes with a possible melanoma link, plus case reports of rhabdomyolysis and priapism. It is not an approved US drug, and the FDA warns against it.
Read Full recordStudied uses & evidence
Studied uses(5)
Skin tanning
MediumMC1R activation drives eumelanin; visible darkening after 5 injected doses, strongest in fair skin.
Erectile function
HighIn a small human trial, 17 of 20 men with erectile dysfunction achieved erection without stimulation.
Sexual desire/arousal
MediumSmall controlled studies found increased desire in men; MT-II research later led to PT-141.
Evidence limits
- Evidence Level
- Early Clinical (Phase I/II)
Phase I (Dorr 1996, n=3): tanning confirmed. Double-blind RCT (Wessells 2000, n=20): potent erectile effects. Never advanced to Phase III. Derivative PT-141 completed full development. Case reports of serious AEs (rhabdomyolysis, renal infarction, melanoma association).
Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Cautions & risk summary
Do not use if
History of melanoma or dysplastic nevi
AbsoluteStimulates melanocyte activity. Can darken existing moles and may promote melanoma in predisposed individuals.
Autoimmune skin conditions
ModerateMelanocyte stimulation may worsen autoimmune skin conditions like vitiligo.
Cardiovascular disease
ModerateCan increase blood pressure and heart rate through melanocortin receptor activation.
General cautions
Pregnancy
AbsoluteNo safety data. Affects multiple hormone systems.
Risk summary(6)
Risks = level of concern: High · Moderate · Low · Theoretical
NOT FDA-approved; FDA explicitly warns against use
HighRhabdomyolysis (case reports)
ModerateRenal infarction (case report)
LowPossible melanoma association; stimulates melanocyte proliferation
ModerateNausea, facial flushing in most users
HighPriapism (prolonged painful erection)
Moderate
Further reading
- Overview in Full record
- Safety & interactions in Full record
- Research & benefits in Full record
- Regulation & availability in Full record
- Sources in Full record
- Frequently asked questions in Full record
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.